pharmaceuticals

In May 2015, Mylan Pharmaceuticals appealed to the Third Circuit after the lower court dismissed its case against Warner Chilcott, which was predicated on a practice called product-hopping. While we await the ruling which is due to come later this year, here is some background information on the developing area ...

On October 24, 2014, Amgen filed a complaint against Sandoz, the generic arm of Novartis Group, asserting three causes of action: 1) unfair competition under Cal. Bus. & Prof. Code § 17299 et seq.; 2) conversion; and 3) patent infringement. Amgen filed the complaint in response to Sandoz’s July 2014 ...